Abstract
We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.
Keywords: Antiretroviral therapy; Coronavirus; Enzyme-linked immunosorbent assay (ELISA); Plaque reduction assay; Severe acute respiratory syndrome.
All Keywords
【저자키워드】 coronavirus, Severe acute respiratory syndrome, Antiretroviral therapy, Enzyme-linked immunosorbent assay (ELISA), Plaque reduction assay, 【초록키워드】 SARS-CoV-2, immune response, antibody, Symptoms, enzyme-linked immunosorbent assay, Clinical course, HIV infection, COVID-19 patient, antibody production, reduction, acute respiratory syndrome, plaque, patient with COVID-19, reached, 【제목키워드】 SARS-CoV-2 neutralizing antibody, patient with COVID-19,
【저자키워드】 coronavirus, Severe acute respiratory syndrome, Antiretroviral therapy, Enzyme-linked immunosorbent assay (ELISA), Plaque reduction assay, 【초록키워드】 SARS-CoV-2, immune response, antibody, Symptoms, enzyme-linked immunosorbent assay, Clinical course, HIV infection, COVID-19 patient, antibody production, reduction, acute respiratory syndrome, plaque, patient with COVID-19, reached, 【제목키워드】 SARS-CoV-2 neutralizing antibody, patient with COVID-19,
{{{ 추상적인 }}}
우리는 COVID-19에 대한 잘 통제된 HIV 양성 환자의 임상 경과 및 면역 반응을 발표했습니다. SARS-CoV-2에 대한 임상 양상과 항체 생산은 HIV 감염이 없는 다른 COVID-19 환자와 유사했습니다. 중화항체는 발병 26일째부터 47일째에 정체기에 이르렀으나 증상 후 157일째에 감소하였다.
{{ 키워드: }} 항레트로바이러스 요법; 코로나바이러스; 효소 결합 면역흡착 분석(ELISA); 플라크 감소 분석; 심한 급성 호흡기 증후군.